Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us?

Abstract

In 1998, the U.S. Food and Drug Administration granted regulatory approval to the first tumor necrosis factor-α antagonist, infliximab, for the treatment of moderately to severely active Crohn's disease. As of 2013, there were 3 additional tumor necrosis factor-α antagonists commercially available for the treatment of inflammatory bowel disease in the… (More)
DOI: 10.1097/MIB.0000000000000218

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.